Sangamo enters into asset sale agreements with Lilly and Astellas

Click here to view

Additional information about the Chapter 11 reorganization and asset sales is available through Sangamo's noticing agent at https://www.veritaglobal.net/SangamoTherapeutics.

Presentation

Poster: SOD1 Gene Repression Mediated by Zinc Finger Repressors (ZFRs) as a Therapeutic Approach for SOD1-Mediated ALS

Download PDF